Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…(G) <i>klf2a</i> expression decreases after 15-h lidocaine treatment (90%, <i>n</i> = 67). …”

Reduced follicles, decreased ovulation and decreased fertilization of female Meox-2-cre/Separase S1121A mutant mice. by Juan Xu (225010)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

cAMP and PKA/AKAP1 decrease mobility and promote mitochondrial translocation of Drp1. by Ronald A. Merrill (224222)

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

3D snapshots of the tumor system with single-agent BHQ880 treatment at (a) time step 40, (b) time step 50 and (c) time step 120. by Minna Qiao (836556)

Decreasing pixel differences caused by worm movement correspond to decreasing locomotive health. by Areta Jushaj (8525655)

SDG decreases iron-induced oxidative stress in H9c2 cells. by Stephanie Puukila (568109)

of decreased GFR by age and gender. by Hui Song (53547)

Subjects:

Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”

Resveratrol decreases PKM2 expression. by Mohd Askandar Iqbal (324124)

Subjects:

Pretreatment with SDG prevents iron induced decrease in H9c2 cell size. by Stephanie Puukila (568109)

SDG decreases iron-induced MMP gene expression in H9c2 cells. by Stephanie Puukila (568109)

Probability of release is decreased by hydrophobic mutations. by Matthew R. Bowers (8423115)

Decreasing cell adhesion decreases [Ca²⁺]_i oscillation frequency. by Charles Godbout (540424)

Silencing of Rap1A decreases ERK and p38 activation. by Yougen Wu (830191)

GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

Subjects:

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Inhibition of ILK Decreases Bipolar and Multipolar Cytokinesis while Increasing Survival of Multinucleated Cells. by William K. A. Sikkema (574881)